By Dean Seal
Anavex Life Sciences recorded a wider loss in its fiscal fourth quarter, though the shortfall was still smaller than analysts had been expecting.
The clinical-stage biopharmaceutical company posted a loss of $11.6 million for the three months ended Sept. 30 compared with a loss of $10.1 million in the same quarter a year ago.
Per share, the loss was 14 cents. Analysts polled by FactSet had been expecting a loss of 16 cents a share.
Overheads and R&D costs for the quarter were higher year-over-year, leaving the company with cash and cash equivalents of $132.2 million by quarter's end. The company said it is currently looking at about four years of runway at the current cash burn rate.
Shares rose 9.3% to $9.43 in premarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 23, 2024 07:41 ET (12:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.